1.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Article
in English
| MEDLINE
| ID: mdl-38084090
ABSTRACT
SUMMARY: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.